Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06510660
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-04-01
Brief Title:
Adebrelimab Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Adebrelimab with or Without Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma a Prospective Phase 2 Trial
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RICE
Brief Summary:
To evaluate the efficacy and safety of adebrelimab with or without induction chemotherapy followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
Detailed Description:
This is a prospective two-cohort multicenter clinical study Subjects received different treatments based on their CPS scores During induction therapy subjects in cohort 1 CPS score 10 received adebrelimab while cohort 2 CPS score 10 were administered adebrelizumab carboplatincisplatin paclitaxelnab-paclitaxel Both groups received carboplatincisplatin paclitaxelnab-paclitaxel combined radiotherapy during concurrent chemoradiotherapy The primary endpoint was cCR rate
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None